The AMPLIFY trial is expected to begin in the coming months medication information.

The AMPLIFY trial is expected to begin in the coming months, and to enroll is approximately 4,800 patients with acute DVT or PE and the safety and efficacy of apixaban 10 mg examined twice a day for 1 week to 5 mg, twice followed daily 6 months with enoxaparin and warfarin, the two drugs used as the current standard of care compared medication information .

Bristol-Myers Squibb Company and Pfizer announced the start of a new Phase 3 clinical trial evaluating the effect of apixaban in patients with venous thromboembolism , a potentially fatal disease process judge starts with blood clots in the leg veins or lungs. Apixaban, which was currently being developed by the two companies, is an oral, highly selective factor Xa inhibitor, a new class of agents with therapeutic potential to prevent and treat blood clots.

About Harris Corporation toHarrisburg is an international communications and information technology company, this government and commercial markets in over 150 countries of. Is headquartered in Melbourne, Florida, the company has an annual turnover of 5, USD and 16,000 employees. Of which nearly 7,000 engineers and scientists are Harris devoted to the development best – in-class assured communications products, systems and services. Be secondary to Palestinians : solution is in the judicial, of sovereignty and self-determination.